Pharsight Launches Phoenix WinNonlin as Cornerstone of New Software Platform for Model-Based Drug Development
Phoenix WinNonlin 6.0 Provides Enhancements to Industry-Standard PK/PD Analysis Tool, Adds New Interface and Workflow Management Engine
ST. LOUIS -- Pharsight, a market-leading provider of software and scientific services to improve productivity and decision-making in clinical drug development, today announced the launch of Phoenix WinNonlin, the next generation of the company's industry-standard software tool for pharmacokinetic and pharmacodynamic (PK/PD) modeling and noncompartmental analysis. Phoenix WinNonlin 6.0 is the cornerstone of PhoenixTM, Pharsight's new desktop software platform that is designed to advance model-based drug development by providing an integrated environment for data analysis, modeling and simulation.
The major features of Phoenix WinNonlin 6.0 include a new graphical user interface that makes creation and re-use of PK/PD analysis workflows seamless and intuitive, powerful native graphics and improved data management tools. Phoenix WinNonlin will be backward-compatible with WinNonlin versions 4 and 5. Phoenix WinNonlin will continue to operate with Pharsight's enterprise PK/PD data management system, Pharsight Knowledgebase ServerTM (PKSTM), and can also be used independently of PKS.
In addition to the release of Phoenix WinNonlin 6.0, newly released Phoenix ConnectTM software integrates applications built on the Phoenix platform with commonly used third-party analysis and modeling tools such as S-PLUS®, NONMEM® and SAS®, and enables data import/export with emerging industry standards such as CDISC.
"The release of Phoenix WinNonlin represents an important milestone in Pharsight's vision for software to enable model-based drug development and its utility in translational science," said Daniel Weiner, Ph.D., senior vice president and chief technology officer of Pharsight. "Phoenix WinNonlin version 6.0 merges the trusted algorithms from WinNonlin with new powerful data management tools and high-quality graphics to support comprehensive PK/PD analysis. The Phoenix platform has been developed to provide a collaborative environment for drug development scientists and to shorten the learning curve to more complex and impactful modeling, which ultimately supports more confident and efficient clinical development decisions."
Concurrent with the release of Phoenix WinNonlin 6.0, Pharsight has also released version 4.0 of Pharsight Knowledgebase ServerTM (PKSTM). PKS is an enterprise data management system for secure storage and tracking of PK/PD data and analyses that is tightly integrated with Phoenix WinNonlin and earlier WinNonlin versions, as well as Pharsight's complementary software tools for PK analysis automation and reporting. The major features of PKS 4.0 include new web user interface enhancements for navigation of study and scenario data, improved data transfer utilities, and configurable data mining capabilities.
"Pharsight plans to release new Phoenix-enabled versions of all our products that process, analyze and report on pharmacokinetic and pharmacodynamic data to enable knowledge sharing and efficiencies across the PK/PD analytic spectrum," added Dr. Weiner. "In particular, we have had an excellent early response to the beta program for Phoenix NLMETM, our population PK/PD modeling tool currently under development that will optionally interface with Phoenix WinNonlin."
About PhoenixTM WinNonlin®
Phoenix WinNonlin 6.0 is the next generation of Pharsight's industry standard software for PK/PD modeling and noncompartmental analysis. Phoenix WinNonlin improves scientific productivity during critical drug development tasks by providing a comprehensive analysis environment that implements efficient reusable workflows and high quality outputs to reduce barriers to learning and collaboration and to enable more impactful quantitative decision making. More information about Phoenix WinNonlin is available at www.pharsight.com.
Pharsight, a CertaraTM company, is a market-leading provider of software products and scientific consulting services to help pharmaceutical and biotechnology companies improve their drug development process, regulatory compliance and strategic decision-making. Established in 1995, the company's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products. Pharsight leverages expertise in its software tools and in the disciplines of pharmacology, drug and disease modeling, human genetics, biostatistics, strategic decision-making and regulatory strategy. Headquartered in St. Louis, Missouri, with more than 1200 customers worldwide, Pharsight products and services are used by all of the world's top 50 pharmaceutical firms.
Certara is dedicated to improving human health through a broad spectrum of products and services, from molecular discovery to clinical research. Formed in 2008, Certara unites Tripos and Pharsight Corporation. Tripos is a global leader in innovative scientific solutions enabling life science researchers to improve the efficiency of molecular discovery. Pharsight is the leading provider of software and scientific services to improve productivity and decision-making in clinical drug development. Certara expects to provide its clients with important new products, key enabling technologies and scientific expertise to expedite the flow of information throughout drug discovery and development. Certara is focused on reducing the barriers between the phases of research that will speed discoveries in chemistry and enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products.
Registered Trademarks and Trademarks
Pharsight, Phoenix, Phoenix WinNonlin, Phoenix Connect, Phoenix Validation Suite, Phoenix NLME, WinNonlin, PKS and Pharsight Knowledgebase Server are trademarks or registered trademarks of Tripos, L.P. All other brands and product names are trademarks or registered trademarks of their respective holders.